Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevirumab (MSL 109) for CMV Retinitis in AIDS
NCT00000836Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cytomegalovirus retinitis comparing Sevirumab + SOC with Placebo + SOC (2 arms). Primary endpoint: Time to progression of retinitis. Status: completed.
02
Drugs
sevirumab
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00000836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000836.